Methyllycaconitine is the first low molecular weight ligand shown to selectively discriminate between muscle nicotinic receptors and neuronal alpha-bungarotoxin-binding sites.
No takes yet. Share an insight, caveat, or question.
Offers selective probe for neuronal over muscle nicotinic sites in rodents; leaves open human translation and therapeutic utility.
Ward et al. (1990) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: